Not quite yet.
The media is full of reports today about a clinical trial showing that a 600 milligram daily dose of aspirin reduced the incidence of hereditary colon cancer by 63%.
While this is a somewhat intriguing result, we would point out that the trial lasted only about 4.5 years and the result is based on a total of 48 study subjects who developed colon cancer — 18 in the aspirin group and 30 in the placebo group. The incidence of colon cancer was 4.3% in the aspirin group and 6.9% in the placebo group.
Are you convinced?